RIPK3 and cancer: The findings that RIPK3 expression is silenced in many types of tumor cell lines and cancers and that necroptosis augments the anti-tumor activity of T cells leads to the speculation that necroptosis inhibition may be a key event for tumor development in some types of cancers [46–48, 51].